Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q1 FY2014 Earnings Presentation
10 slides from Daiichi Sankyo's earnings presentation, Jul 31, 2014
Slide 1: Results Briefing: Results for 1Q FY2014
Results Briefing Results for 1Q FY2014 (April 1 – June 30, 2014) DAIICHI SANKYO CO., LTD Manabu Sakai Representative Director, Vice President Head of Corporate Management Division Thursday, July 31, 2014 15:00 ~ 16:00
Slide 2: Overview of FY2014 1Q Results
Overview of FY2014 1Q Results Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn FY2013 FY2014 FY2013 FY2014 YoY YoY Plan* 1Q Result 1Q Result 1Q Result 1Q Result +0.7% Revenue 252.6 254.4 +1.8 Revenue 210.4 213.7 +3.3 920.0 Cost of sales 87.6 85.9 -1.7 Cost of sales 65.9 64
Slide 3: FY2014 1Q Revenue
FY2014 1Q Revenue Positive Factors Negative Factors Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn 230.0 240.0 250.0 260.0 190.0 200.0 210.0 220.0 FY2013 Q1 Results 210.4 FY2013 Q1 Results 252.6 Japan others 4.1 Japan, others (incl. Vaccine, OTC) 4.3 (incl. Vaccine, OTC)
Slide 4: FY2014 1Q Operating Profit
FY2014 1Q Operating Profit Positive Factors Negative Factors Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn 0.0 10.0 20.0 30.0 0.0 10.0 20.0 30.0 40.0 FY2013 Q1 Results 15.2 FY2013 Q1 Results 14.6 Daiich Sankyo Group 4.6 Gross Profit Gross Profit 4.6 Ranbaxy Group 1.1 Gr
Slide 5: FY2014 1Q Profit attributable to owners of the Company
FY2013 1Q Profit attributable to Positive Negative owners of the Company Factors Factors Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn 0.0 10.0 20.0 30.0 0.0 10.0 20.0 30.0 40.0 FY2013 Q1 Results 15.0 FY2013 Q1 Results 13.9 Operating Profit 14.2 Operating Profit 17.5 Fi
Slide 6: Major Products in Japan
Major Products in Japan JPY Bn 2013Q1 2014Q1 FY2014 YoY To Plan Result Result Plan Olmetec anti-hypertension 16.6 18.7 +2.1 79.0 24% anti-ulcer Nexium （Proton Pump Inhibitor） 10.9 15.3 +4.3 67.0 23% analgesic and anti- Loxonin inflammatory 14.9 12.2 -2.7 52.0 24% treatment for Memary Alzheimer 6.6 7
Slide 7: Major Business Units
Major Business Units JPY Bn FY2013Q1 FY2014Q1 FY2014 YoY To plan Result Result Plan Japan Company + Vaccine business 109.4 108.0 -1.4 508.0 21% Daiichi Sankyo Healthcare 9.8 9.4 -0.4 48.0 20% Daiichi Sankyo Inc. 46.6 41.6 -5.0 164.0 25% Olmesartan 30.7 25.7 -5.0 105.0 24% Welchol 11.4 11.3 -0.1 41.0
Slide 8: Edoxaban: Global NDA / Launch Schedule
Edoxaban Global NDA / Launch Schedule FY2014 Target Indications FY2015 ～ Apr-Sep Oct-Mar Prevention of stroke and systemic embolic events Approval Launch in patients with atrial Authority’s EU, Asia, Latin Launch America Review fibrillation NDA filing JP,US,EU & others JPN Dec/2013 Acute treatment a
Slide 9: Major R&D Pipeline
Major R&D Pipeline As of July 2014 Therapeutic area Phase 1 Phase 2 Phase 3 Application ■ DS-7309 ■ CS-3150 (JP) ■ Prasugrel(JP) ■ Edoxaban (US/EU /JP) (Diabetes / Glucokinase activator) (Hypertensive / DM nephropathy / (CS-747 / ischemic stroke (DU-176b / AF / oral factor Xa MR antagonist) / anti-p
Slide 10: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f
Daiichi Sankyo Company — Q1 FY2014 Earnings Presentation on 6ix